U.S. PHARMACOPEIA

Search USP29  
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules
» Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules contain not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of chlordiazepoxide hydrochloride (C16H14ClN3O·HCl) and clidinium bromide (C22H26BrNO3).
Packaging and storage— Preserve in tight, light-resistant containers.
Identification— The retention times of the major peaks in the chromatogram of the Assay preparation correspond to those of the Standard preparation as obtained in the Assay.
Dissolution, Procedure for a Pooled Sample 711
Medium: water; 900 mL.
Apparatus 1: 100 rpm.
Time: 30 minutes.
Determine the amounts of chlordiazepoxide hydrochloride and clidinium bromide dissolved using the following method.
Solution A— Dissolve 1.92 g of sodium 1-pentanesulfonate in 900 mL of water. Adjust the solution with dilute sulfuric acid (1 in 100) to a pH of 3.8 ± 0.1, dilute with water to 1.0 liter, and mix.
Mobile phase— Prepare a filtered and degassed mixture of Solution A, tetrahydrofuran, and methanol (75:18:6). Make adjustments if necessary (see System Suitability under Chromatography 621).
Chromatographic system— The liquid chromatograph is equipped with a 212-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 2 mL per minute. Chromatograph replicate injections of the Standard solution, and record the peak responses as directed for Procedure: the resolution between the two components is not less than 5.0, and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 100 µL) of a Standard solution and a filtered portion of the solution under test into the chromatograph, record the chromatograms, and measure the responses for the major peaks. The relative retention times are about 0.6 for clidinium bromide and 1.0 for chlordiazepoxide hydrochloride. Calculate the amounts of chlordiazepoxide hydrochloride (C16H14ClN3O·HCl) and clidinium bromide (C22H26BrNO3) dissolved in comparison with a Standard solution having known concentrations of USP Chlordiazepoxide Hydrochloride RS and USP Clidinium Bromide RS, similarly prepared and chromatographed.
Tolerances— Not less than 75% (Q) each of the labeled amounts of C16H14ClN3O·HCl and C22H26BrNO3 are dissolved in 30 minutes.
Uniformity of dosage units 905: meet the requirements.
Related compounds—
A: LIMIT OF CHLORDIAZEPOXIDE RELATED COMPOUND A AND 2-AMINO-5-CHLOROBENZOPHENONE Proceed with the Capsules as directed in the test for Related compounds under Chlordiazepoxide Hydrochloride Capsules. Not more than 3.0% of chlordiazepoxide related compound A is found; and not more than 0.1% of 2-amino-5-chlorobenzophenone is found.
B: LIMIT OF 3-QUINUCLINDINYL BENZILATE
Adsorbent: 0.25-mm layer of chromatographic silica gel mixture.
Test solution— Place a glass wool plug in the bottom of a 2.5-cm × 35 ± 5-cm glass chromatographic tube, add 2 g of chromatographic siliceous earth triturated with 1 mL of 1 N hydrochloric acid, and lightly pack with a glass tamping rod. Empty a number of Capsules, equivalent to about 15 mg of clidinium bromide, into a 100-mL beaker, add 3 mL of 1 N hydrochloric acid, and swirl to dissolve. Add 4 g of chromatographic siliceous earth, mix with a spatula, and add the Capsule-siliceous earth mixture to the chromatographic tube. Dry-wash the beaker with an additional 0.5 to 1.0 g of chromatographic siliceous earth, adding the washing to the top of the column. Lightly pack with the tamping rod, and overlay the column with glass wool. Insert the lower exit tube of the column into a 125-mL separator, and elute the column with 100 mL of chloroform previously distilled over 1 N sulfuric acid and saturated with water. Extract the chloroform eluate with 20 mL of freshly prepared ascorbic acid solution (1 in 20), preserving the extract. Extract the eluate with a second 15-mL portion of the ascorbic acid solution, combine the extracts in the separator, and discard the chloroform layer. Neutralize the acid extracts by adding sodium bicarbonate until the solution is slightly alkaline to the pH paper. Extract the slightly alkaline solution with two 25-mL portions of chloroform, combine the chloroform extracts, and pass through dry, fluted filter paper into a 100-mL beaker. Evaporate the chloroform to dryness with the aid of a stream of nitrogen, and transfer the residue to a glass-stoppered 1.0-mL volumetric flask, using methanol to facilitate the transfer. Dilute with methanol to volume.
Reference solution— Dissolve 3.0 mg of USP 3-Quinuclidinyl Benzilate RS in 100 mL of methanol, and mix.
Developing solvent system: methanol.
Procedure— Separately apply 15 µL of the Reference solution and 100 µL of the Test solution to a suitable chromatographic plate, place the plate in a paper-lined, methanol-saturated chromatographic chamber, and proceed as directed for Thin-layer Chromatography under Chromatography 621. Remove the plate, air-dry, spray with potassium iodoplatinate TS, and allow the spots to develop for 10 minutes. Any spot in the chromatogram obtained from the Test solution occurring at an RF value of about 0.3 is not greater in size or intensity than the spot in the chromatogram obtained from the Reference solution: not more than 0.03% of 3-quinuclidinyl benzilate is found.
C: LIMIT OF CLIDINIUM BROMIDE RELATED COMPOUND A
Adsorbent, Developing solvent system, Chromatographic plates, and Spray reagent— Prepare as directed in the test for Related compounds under Clidinium Bromide.
Extracting solvent mixture: a mixture of dehydrated alcohol and cyclohexane (1:1).
Test solution— Empty a number of Capsules, equivalent to about 25 mg of clidinium bromide, into a glass-stoppered centrifuge tube, and add 5 mL of Extracting solvent mixture. Heat the tube gently, with shaking, to 50, centrifuge, and decant the clear supernatant into a second tube. Repeat the addition of Extracting solvent mixture twice, heating, centrifuging, and decanting as before, and combine the three extracts in a single tube. Gently heating, evaporate the combined extracts under a stream of nitrogen to dryness. Dissolve the residue in 0.5 mL of methanol.
Standard solution— Dissolve 50 mg of USP Clidinium Bromide RS in 1.0 mL of 0.1 N methanolic hydrochloric acid. Prepare this solution at the time of use.
Reference solution— Dissolve 50 mg of USP Clidinium Bromide RS in 1.0 mL of 0.1 N methanolic hydrochloric acid, and add 20 µL of a solution of 25 mg of USP Clidinium Bromide Related Compound A RS in 1.0 mL of methanol. Prepare this solution at the time of use.
Application volume: 20 µL.
Procedure— Separately apply the Standard solution, the Reference solution, and the Test solution as directed in Thin-Layer Chromatography under Chromatography 621. Place the plates in an unsaturated chromatographic chamber containing freshly prepared Developing solvent system, and develop the chromatogram until the solvent front has moved about 15 cm. Remove the plates, and dry at 105 for 10 minutes. Cool to room temperature, and spray with Spray reagent. Any spot in the chromatogram obtained from the Test solution occurring at an RF value of about 0.4 is not greater in size or intensity than the corresponding spot in the chromatogram obtained from the Reference solution; and the Standard solution shows no spot at the RF value corresponding to that of clidinium bromide related compound A: not more than 1.0% of clidinium bromide related compound A is found.
Residual solvents 467: meet the requirements.
(Official January 1, 2007)
Assay— [NOTE—Use low-actinic glassware in this procedure.]
Sodium 1-pentanesulfonate solution— Dissolve 1.92 g of sodium 1-pentanesulfonate in about 900 mL of water in a 1-liter volumetric flask. Adjust with 1 N sulfuric acid to a pH of 3.8 ± 0.1, dilute with water to volume, mix, and filter.
Mobile phase— Prepare a filtered and degassed mixture of Sodium 1-pentanesulfonate solution, tetrahydrofuran, and methanol (70:24:6). Make adjustments if necessary (see System Suitability under Chromatography 621).
Solvent mixture— Prepare a mixture of water and methanol (1:1).
Standard preparation— Dissolve accurately weighed quantities of USP Chlordiazepoxide Hydrochloride RS and USP Clidinium Bromide RS in Solvent mixture, and dilute quantitatively, and stepwise if necessary, with Solvent mixture to obtain a solution having known concentrations of about 0.1 mg of USP Chlordiazepoxide Hydrochloride RS and 0.05 mg of USP Clidinium Bromide RS per mL.
Assay preparation— Weigh the contents of not fewer than 20 Capsules, and calculate the average weight per Capsule. Mix the combined contents of the Capsules, and transfer an accurately weighed portion, equivalent to about 5 mg of chlordiazepoxide hydrochloride (C16H14ClN3O·HCl), to a 50-mL volumetric flask. Add about 25 mL of Solvent mixture, sonicate for 5 minutes, and shake by mechanical means for 10 minutes. Dilute with Solvent mixture to volume, mix, and filter, discarding the first 20 mL of the filtrate.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 212-nm detector and an 8-mm × 100-mm column that contains packing L1. The flow rate is about 3 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the resolution, R, between the clidinium bromide and chlordiazepoxide hydrochloride peaks is not less than 5.0, and the relative standard deviation for replicate injections is not more than 2.0%. The relative retention times are about 0.5 for clidinium bromide and 1.0 for chlordiazepoxide hydrochloride.
Procedure— Separately inject equal volumes (about 20 µL) of the Assay preparation and the Standard preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of chlordiazepoxide hydrochloride (C16H14ClN3O·HCl) in the portion of Capsules taken by the formula:
50C(rU / rS),
in which C is the concentration, in mg per mL, of USP Chlordiazepoxide Hydrochloride RS in the Standard preparation; and rU and rS are the chlordiazepoxide hydrochloride peak responses obtained from the Assay preparation and the Standard preparation, respectively. Calculate the quantity, in mg, of clidinium bromide (C22H26BrNO3) in the portion of Capsules taken by the same formula, reading clidinium bromide instead of chlordiazepoxide hydrochloride.
Auxiliary Information— Staff Liaison : Ravi Ravichandran, Ph.D., Senior Scientist
Expert Committee : (MDPP05) Monograph Development-Psychiatrics and Psychoactives
USP29–NF24 Page 474
Pharmacopeial Forum : Volume No. 30(1) Page 83
Phone Number : 1-301-816-8330